Prevalence and management of treatment-resistant depression.

Treatment-resistant depression (TRD) is a major public health problem in terms of its prevalence and in terms of individual suffering and cost to society. Best estimates indicate 12-month prevalence rates of approximately 3% for Stage 1 TRD (failure to respond to 1 adequate trial of an antidepressant) and approximately 2% for Stage 2 TRD (failure to respond to 2 adequate trials). The current article provides a brief review of the definitions, prevalence, and various treatment options for TRD, including switching, augmentation, and combination therapies and use of nonpharmacologic treatments. Given the public health importance of TRD, the relative absence of adequately powered, double-blind trials is striking.

[1]  M. Frye,et al.  Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. , 2001, The American journal of psychiatry.

[2]  W. Nolen,et al.  Treatment strategy in depression , 1988, Acta psychiatrica Scandinavica.

[3]  W. Nolen,et al.  Treatment strategy in depression , 1988, Acta psychiatrica Scandinavica.

[4]  J. Neumaier,et al.  A Controlled Study of Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Major Depression , 2006, Biological Psychiatry.

[5]  M. Thase.  Introduction: defining remission in patients treated with antidepressants. , 1999, The Journal of clinical psychiatry.

[6]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[7]  J. Zajecka,et al.  CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. , 1991, Journal of clinical psychopharmacology.

[8]  M. Fava,et al.  A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. , 2005, The Journal of clinical psychiatry.

[9]  Alexander L. Miller,et al.  Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. , 2004, Archives of general psychiatry.

[10]  M. Zink.  Augmentation of olanzapine in treatment-resistant schizophrenia. , 2005, Journal of psychiatry & neuroscience : JPN.

[11]  M. Fava,et al.  Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study , 2006, CNS Spectrums.

[12]  P. Moleman,et al.  Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. , 2004, The Journal of clinical psychiatry.

[13]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[14]  W. Nolen,et al.  L-5HTP in Depression Resistant to Re-Uptake Inhibitors , 1985, British Journal of Psychiatry.

[15]  C. Naylor,et al.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. , 1996, Archives of general psychiatry.

[16]  J. Feighner,et al.  Venlafaxine for treatment-resistant unipolar depression. , 1994, Journal of clinical psychopharmacology.

[17]  L. Carpenter.  Neurostimulation in resistant depression , 2006, Journal of psychopharmacology.

[18]  J. Lorberbaum,et al.  A review of functional neuroimaging studies of vagus nerve stimulation (VNS). , 2003, Journal of psychiatric research.

[19]  Mustafa M. Husain,et al.  Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial , 2005, Biological Psychiatry.

[20]  M. Fava,et al.  Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. , 2000, The Journal of clinical psychiatry.

[21]  Mustafa M. Husain,et al.  Vagus nerve stimulation: a new tool for brain research and therapy∗ , 2000, Biological Psychiatry.

[22]  Dwight L. Evans,et al.  Comparison of pramipexole, fluoxetine, and placebo in patients with major depression , 2000, Depression and anxiety.

[23]  K. Kaufman,et al.  Modafinil augmentation of antidepressant treatment in depression. , 2000, The Journal of clinical psychiatry.

[24]  M. Thase,et al.  Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. , 2002, Archives of general psychiatry.

[25]  G. Debonnel,et al.  Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. , 1999, Journal of clinical psychopharmacology.

[26]  J. Rojo,et al.  Use of antidepressant combinations: which, when and why? Results of a Spanish survey , 2005, Acta psychiatrica Scandinavica. Supplementum.

[27]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[28]  A. Stoll,et al.  Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. , 1996, The Journal of clinical psychiatry.

[29]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[30]  Raymond W Lam,et al.  Combining antidepressants for treatment-resistant depression: a review. , 2002, The Journal of clinical psychiatry.

[31]  J. Galea,et al.  Lamotrigine Augmentation Strategy for Patients with Treatment-Resistant Depression , 2005, CNS Spectrums.

[32]  M. Fava,et al.  The combination of duloxetine and bupropion for treatment‐resistant major depressive disorder , 2006, Depression and anxiety.

[33]  Stephan Arndt,et al.  Tricyclic Antidepressant Concentrations in Plasma: An Estimate of Their Sensitivity and Specificity as a Predictor of Response , 1994, Journal of clinical psychopharmacology.

[34]  G. Papakostas.  Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. , 2005, Essential psychopharmacology.

[35]  M. Fava,et al.  Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine , 2003, Journal of clinical psychopharmacology.

[36]  W. Nolen,et al.  Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. , 1993, Journal of affective disorders.

[37]  G. Bader,et al.  Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. , 1998, Journal of clinical psychopharmacology.

[38]  Cole A. Giller,et al.  Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome , 2001, Neuropsychopharmacology.

[39]  A. Schatzberg,et al.  A Prospective Trial of Bupropion SR Augmentation of Partial and Non-Responders to Serotonergic Antidepressants , 2003, Journal of clinical psychopharmacology.

[40]  S. Ericksen,et al.  Efficacy of ECT: a meta-analysis. , 1985, The American journal of psychiatry.

[41]  J. Kleinman,et al.  The neuropathology of schizophrenia. , 1988, Schizophrenia bulletin.

[42]  P. Cowen,et al.  Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. , 2003, The Journal of clinical psychiatry.

[43]  A. Rush,et al.  MAOIs in the Contemporary Treatment of Depression , 1995, Neuropsychopharmacology.

[44]  H. Solvason,et al.  A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression , 2004, Journal of clinical psychopharmacology.

[45]  A. Anand,et al.  Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. , 2004, The Journal of clinical psychiatry.

[46]  C. Nemeroff,et al.  Essentials of Clinical Psychopharmacology , 2001 .

[47]  John R. Geddes,et al.  Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis , 2003, The Lancet.

[48]  M. Thase,et al.  Management of treatment-resistant depression: psychotherapeutic perspectives. , 2001, The Journal of clinical psychiatry.

[49]  M. Fava,et al.  Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. , 2001, The Journal of clinical psychiatry.

[50]  A. Berghöfer,et al.  Lithium augmentation therapy in refractory depression—Update 2002 , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[51]  E. Berndt,et al.  The economic burden of depression in 1990. , 1993, The Journal of clinical psychiatry.

[52]  C. Nemeroff,et al.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. , 2001, Biological psychiatry.

[53]  D. Klein,et al.  A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. , 1993, The American journal of psychiatry.

[54]  A. Rush,et al.  Compliance With Pharmacotherapy in Mood Disorders , 1995 .

[55]  J. Amsterdam,et al.  MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study. , 2005, Journal of affective disorders.

[56]  P. Fitzgerald,et al.  A Randomized, Controlled Trial of Sequential Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression Method Study Design , 2022 .

[57]  M. Thase,et al.  Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. , 1992, The Journal of clinical psychiatry.

[58]  L. San,et al.  Reboxetine adjunct for partial or nonresponders to antidepressant treatment. , 2004, Journal of affective disorders.

[59]  Wei Zhang,et al.  A novel augmentation strategy for treating resistant major depression. , 2001, The American journal of psychiatry.

[60]  J. Montes,et al.  Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[61]  Enrico Smeraldi,et al.  Transcranial magnetic stimulation in treatment-resistant depressed patients: A double-blind, placebo-controlled trial , 2005, Psychiatry Research.

[62]  Alexis J. Kant,et al.  Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance , 2005, Journal of clinical psychopharmacology.

[63]  D. Blazer,et al.  The economic burden of depression. , 1986, General hospital psychiatry.

[64]  M. Fava,et al.  Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review , 2000, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[65]  J. Fawcett,et al.  Efficacy issues with antidepressants. , 1997, The Journal of clinical psychiatry.

[66]  N. Michael,et al.  Electroconvulsive therapy vs. paroxetine in treatment‐resistant depression — a randomized study , 1997, Acta psychiatrica Scandinavica.

[67]  L. Price,et al.  Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients , 2004, Biological Psychiatry.

[68]  A. Rush,et al.  When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.

[69]  M. Fava,et al.  Switching to bupropion in fluoxetine-resistant major depressive disorder. , 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[70]  R. Joffe,et al.  Response to an open trial of a second SSRI in major depression. , 1996, The Journal of clinical psychiatry.

[71]  P. Houck,et al.  Pramipexole in treatment-resistant depression: a 16-week naturalistic study. , 2002, Bipolar disorders.

[72]  Alan Frazer,et al.  VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms , 2006, Neuropsychopharmacology.

[73]  C. Reynolds,et al.  Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. , 2003, The Journal of clinical psychiatry.

[74]  B. Lebowitz,et al.  A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. , 2006, The American journal of psychiatry.

[75]  D. Puigdemont,et al.  A double-blind, randomized, placebo-controlled trial of Pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors , 1999 .

[76]  C. Nemeroff.  Use of atypical antipsychotics in refractory depression and anxiety. , 2005, The Journal of clinical psychiatry.

[77]  Evette Ludman,et al.  The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. , 2004, Archives of general psychiatry.

[78]  M. Berk,et al.  A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. , 2003, The Journal of clinical psychiatry.

[79]  Markus Kosel,et al.  Magnetic Seizure Therapy Improves Mood in Refractory Major Depression , 2003, Neuropsychopharmacology.

[80]  M. Fava.  Management of nonresponse and intolerance: switching strategies. , 2000, The Journal of clinical psychiatry.

[81]  C. Nemeroff,et al.  Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation , 2007, Neuropsychopharmacology.

[82]  K. Denicoff,et al.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study , 2004, Biological Psychiatry.

[83]  A. Rush.  The varied clinical presentations of major depressive disorder. , 2007, The Journal of clinical psychiatry.

[84]  M. Thase,et al.  Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. , 1992, The American journal of psychiatry.

[85]  A. Gelenberg,et al.  Pindolol augmentation of treatment-resistant depressed patients. , 1997, The Journal of clinical psychiatry.

[86]  R. Shelton,et al.  Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. , 2005, The Journal of clinical psychiatry.

[87]  D. Kupfer,et al.  Is treatment-resistant depression a unique subtype of depression? , 2003, Biological Psychiatry.

[88]  Barry R. Rittberg,et al.  Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study , 2005, Biological Psychiatry.

[89]  D. Avery,et al.  A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. , 2001, Psychopharmacology bulletin.

[90]  L. Yatham.  Diagnosis and management of patients with bipolar II disorder. , 2005, The Journal of clinical psychiatry.

[91]  J. Amsterdam,et al.  Treatment resistant depression: methodological overview and operational criteria , 1999, European Neuropsychopharmacology.

[92]  A. Rush,et al.  The cost consequences of treatment-resistant depression. , 2004, The Journal of clinical psychiatry.

[93]  J. Feighner,et al.  Citalopram treatment of fluoxetine nonresponders. , 2001, The Journal of clinical psychiatry.

[94]  C. Nemeroff.  Improving antidepressant adherence. , 2003, The Journal of clinical psychiatry.

[95]  K. Burdick,et al.  Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. , 2004, The American journal of psychiatry.

[96]  A. Nierenberg,et al.  Evolution of remission as the new standard in the treatment of depression. , 1999, The Journal of clinical psychiatry.

[97]  M. Fava,et al.  Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. , 2004, General hospital psychiatry.

[98]  R. Kessler,et al.  The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. , 1994, The American journal of psychiatry.

[99]  R. Fieve,et al.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. , 2003, The Journal of clinical psychiatry.

[100]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[101]  P. Boyer,et al.  Venlafaxine and paroxetine in treatment-resistant depression , 1999, British Journal of Psychiatry.

[102]  M. Thase,et al.  Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. , 1997, The Journal of clinical psychiatry.

[103]  C. Nemeroff,et al.  Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. , 2005, The Journal of clinical psychiatry.

[104]  A. Rush,et al.  The impact of treatment-resistant depression on health care utilization and costs. , 2002, The Journal of clinical psychiatry.